Join the aTyr Pharma (ATYR) Securities Class Action Lawsuit | For Investors with more than $50k in Losses

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against aTyr Pharma, Inc. (ATYR)

If you purchased or acquired aTyr Pharma, Inc. securities between January 16, 2025 and September 12, 2025, and suffered losses in excess of $50,000, you may be eligible to join this class action lawsuit and seek compensation for your losses.

About aTyr Pharma, Inc.

aTyr Pharma is a biotechnology company headquartered in San Diego, California. They develop novel therapeutics based on tRNA synthetase biology. The company’s primary clinical-stage asset has been efzofitimod, a drug candidate aimed at treating pulmonary sarcoidosis, a rare lung disease.

The company has conducted multiple clinical trials, including a pivotal Phase 3 study known as EFZO-FIT. Over recent years, aTyr Pharma has allegedly suggested progress in its clinical programs and the potential impact of efzofitimod on patient care.

The Allegations

According to the complaint, aTyr Pharma and certain executives made false and misleading statements about the efficacy of efzofitimod and its ability to enable patients to taper off steroids in the EFZO-FIT trial. Throughout the class period, the company allegedly highlighted strong prospects for the trial and its design while downplaying key risks such as a high placebo response.

On September 15, 2025, aTyr Pharma announced that the EFZO-FIT trial failed to meet its primary endpoint. Following this news, the stock price dropped more than 80%, falling from $6.03 on September 12, 2025 to $1.02 on September 15, 2025. Analysts reacted by sharply cutting price targets and questioning the company’s outlook for efzofitimod.

Plaintiffs claim that aTyr’s prior statements misled investors by overstating the likelihood of clinical success and omitting material risks that ultimately impacted share value.

Important Dates

• Class period: January 16, 2025 to September 12, 2025
• Complaint filed: October 9, 2025
• Lead plaintiff deadline: December 8, 2025

Your Rights and Next Steps

If you purchased or otherwise acquired aTyr Pharma securities during the class period, you have important legal rights. You may be eligible to join the class action lawsuit as a class member and seek to recover your financial losses resulting from the alleged securities fraud.

As a class member, you're not required to take action to remain apart of the class. However, if you're interested in serving as the lead plaintiff (i.e., the party who acts on behalf of other class members), you must file a motion with the court no later than December 8, 2025.

Attorneys are prepared to help investors understand their options and rights, while guiding them through the process. By participating, you may be eligible to recover aTyr Pharam investment-related losses during the specified class period. Importantly, there are not upfront costs or out-of-pocket expenses for joining the lawsuit.

You May Be Entitled to Compensation

If you invested in aTyr Pharma between January 16, 2025 and September 12, 2025 and experienced significant losses after the company’s stock price fell, you may be entitled to compensation. Lawyers are actively investigating the claims and are available to answer your questions.

To find out if you qualify and to take the next step in seeking recovery, complete the form below to join the lawsuit.